Delphine Topart

TL;DR: Evidence is provided that PD‐L1 is frequently expressed on metastatic cells circulating in the blood of hormone receptor‐positive, HER2‐negative breast cancer patients and the established CTC/PD‐L 1 assay can be used for liquid biopsy in future clinical trials for stratification and monitoring of cancer patients undergoing immune checkpoint blockade.

TL;DR: The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at an increased risk of recurrence as discussed by the authors .

TL;DR: In the largest real-world study to date, cabozantinib was effective in unselected, heavily pretreated patients with mRCC and Initiation at 60 mg/day was associated with improved outcomes.

TL;DR: The review of a cohort of 142 patients with previous surgery for primary colonic or rectal tumor and without evidence of local recurrence, receiving bevacizumab for metastatic disease concluded that angiogenesis inhibitors should be carefully considered for patients having low colorectal anastomosis and previous irradiation.

TL;DR: Sunitinib rechallenge is a feasible treatment option with potential clinical benefit for mRCC patients and disease progression with first-line sunitinIB may not be associated with complete or irreversible resistance to therapy.